Drugs /

pd-l1 t-hank

Back to Drugs List

Overview

NCI Definition [1]:
A preparation of natural killer (NK) cells that are derived from NK-92 cells, a human cytotoxic cell line composed of allogeneic NK cells derived from a 50-year old male patient with rapidly progressive non-Hodgkin's lymphoma (NHL), that are genetically engineered to express the high-affinity CD16/FcgammaRIIIa (158V) allele, endoplasmic reticulum (ER)-retained interleukin (IL)-2 and a chimeric antigen receptor (CAR) specific for programmed death-ligand 1 (PD-L1), with potential immunomodulating, cytolytic and antineoplastic activities. Upon infusion of the PD-L1 tumor-targeted high-affinity (ha) NK cells, the NK cells recognize and bind to tumor cells, preferentially to PD-L1-expressing tumor cells and human peripheral myeloid-derived suppressor cells (MDSCs). This leads to the secretion and release of perforins, granzymes, cytokines and chemokines, and results in cancer cell lysis and apoptosis. In addition, the incorporation of the high-affinity CD16 allele allows the NK cells to lyse tumor cells via antibody-dependent cell-mediated cytotoxicity (ADCC) mediated by tumor-antigen-specific immunoglobulin G1 (IgG1) antibodies through binding of CD16 with the Fc region of human IgG1 antibodies. IL-2 replenishes the granular stock of NK cells, leading to enhanced perforin- and granzyme-mediated lysis of tumor cells.

Clinical Trials

View Clinical Trials for pd-l1 t-hank

Pd-l1 t-hank has been investigated in 4 clinical trials, of which 4 are open and 0 are closed. Of the trials investigating pd-l1 t-hank, 1 is phase 1 (1 open) and 3 are phase 2 (3 open).

Deficient DNA Mismatch Repair (dMMR), MLH1 Deficient Expression, and MSH2 Deficient Expression are the most frequent biomarker inclusion criteria for pd-l1 t-hank clinical trials.

Adenocarcinoma of the gastroesophageal junction, head and neck squamous cell carcinoma, and malignant solid tumor are the most common diseases being investigated in pd-l1 t-hank clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Pd-L1 T-Hank
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating pd-l1 t-hank and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
allogeneic pd-l1-targeting high-affinity nks, allogeneic pd-l1-t-hank, allogeneic pd-l1 t-hank, allogeneic pd-l1 tumor-targeted high-affinity natural killer cells
Drug Target(s) [2]:
CD274
NCIT ID [1]:
C174011

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.